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Background: To dosimetrically evaluate the effect of reduced margin radiotherapy on hippocampal dose for
glioblastoma multiforme (GBM) patients.
Methods: GBM patients enrolled on the Radiation Therapy Oncology Group (RTOG) 0825 trial at our institution
were identified. Standard RTOG 0825 expansions were 2 cm + 3-5 mm from the gross tumor volume (GTV) to the
clinical tumor volume (CTV) and from the CTV to the planning tumor volume (PTV), respectively. These same patients also
had reduced margin tumor volumes generated with 8 mm (GTV to CTV) + 3 mm (CTV to PTV) expansions. Individual
plans were created for both standard and reduced margin structures. The dose-volume histograms were statistically
compared with a paired, two-tailed Student’s t-test with a significance level of p < 0.05.
Results: A total of 16 patients were enrolled on RTOG 0825. The reduced margins resulted in statistically significant
reductions in hippocampal dose at all evaluated endpoints. The hippocampal Dmax was reduced from a mean of
61.4 Gy to 56.1 Gy (8.7%), D40% was reduced from 49.9 Gy to 36.5 Gy (26.9%), D60% was reduced from 32.7 Gy to
18.7 Gy (42.9%) and the D80% was reduced from 27.3 Gy to 15.3 Gy (44%).
Conclusions: The use of reduced margin PTV expansions in the treatment of GBM patients results in significant
reductions in hippocampal dose. Though the exact clinical benefit of this reduction is currently unclear, this study does
provide support for a future prospective trial evaluating the neurocognitive benefits of reduced margin tumor volumes
in the treatment of GBM patients.
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Glioblastoma Multiforme (GBM) has traditionally been
a devastating disease with median life expectancies of a
year or less from the time of diagnosis [1]. In recent years,
however, there have been several significant advances in
the treatment and stratification of patients with GBM that
have resulted in life expectancies in excess of 21 months
for select cohorts [2]. Specifically, the combination of
temozolomide and radiotherapy has increased the median
survival from 12.1 months for radiotherapy alone to
14.6 months with temozolomide and radiotherapy [3].
More striking is the long-term follow-up data for tem-
ozolomide and radiotherapy, which reveals that 9.8% of* Correspondence: aali24@emory.edu
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reproduction in any medium, provided the orpatients treated with concurrent therapy were alive at 5
years [4]. This point is further magnified when methyl-
guanine methyl transferase gene (MGMT) methylation,
which has been previously shown to be an independent
prognostic indicator and predictor of benefit from tem-
ozolomide, is considered [2,5-8]. In those patients with
MGMT methylation treated with a combination of tem-
ozolomide and radiotherapy the 5-year overall survival
(OS) was shown to be as high as 13.8% [4].
Given the increased life expectancy of GBM patients in
general and specifically those with MGMT methylation,
attention has begun to focus on quality of life issues in
addition to survival [9,10]. Multiple studies have dem-
onstrated memory, learning, and other neurocognitive
deficits in long-term survivors of GBM and other high
grade gliomas previously treated with radiotherapy [6,9-17].
The retrospective review by Imperato et al. found that
2 out of 5 long-term high grade glioma survivors hadThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Likewise, Lieberman et al. found that 2 out of 3 long-term
astrocytoma survivors had diffuse cortical dysfunction so
disabling that the patients could no longer work [14].
Perhaps the largest series was that by Peters et al. that
found that out of 123 long-term GBM survivors with a
median survival of 74.5 months, greater than 25% required
the use of some psychoactive medications, thus indicating
significant neurocognitive sequela [10]. It seems that the
decreased neurocognitive performance of post-radiation
glioma patients may be due, in large part, to memory
dysfunction. Salander et al. evaluated 30 patients with
malignant gliomas that had received radiation and found
no clear impairment in global intellectual abilities or
visual imagery, but did find a profound deficit in long-term
memory [15].
It has been long known that the hippocampus is primar-
ily involved with learning and long-term memory formation
[18-23]. In primate studies, it was found that monkeys with
bilateral removal of the hippocampus and amygdala had
significantly impaired spatial learning and memory [24-26].
In patients, isolated lesions of the hippocampus have
been consistently associated with anterograde amnesia
and learning dysfunction [27-30].
Given the association of hippocampal lesions with
memory dysfunction and the significant decline in neuro-
cognitive performance after cranial irradiation, a study was
performed that investigated the association of hippocampal
radiation dose with neurocognitive impairment [31]. Gondi
et al. found that a dose greater than 7.3 Gy to 40% of the
bilateral hippocampus was associated with long-term
impairment in Wechsler Memory Scale-Word List delayed
recall for fractionated stereotactic radiotherapy treatment
of benign or low-grade adult brain tumors [31]. With these
results, there has recently been significant interest in
minimizing dose to the hippocampus during whole
brain radiation for the palliation of brain metastases and
prophylactic cranial irradiation [32-35]. To date, however,
there have been no explorations of hippocampal sparing
in the setting of GBM even though neurocognitive decline
appears to be just as significant after radiation for GBM
and the life expectancy for a sizeable cohort of GBM
patients is now the same or better than that for patients
with brain metastases.
At our institution, we have previously reported the use
of reduced margin radiotherapy in the management of
GBM patients [36]. McDonald et al. found that use of total
PTV margins of less than 1 cm resulted in radiographic
tumor progression rates comparable with standard 2.3 cm
to 2.5 cm GBM PTV margins. Specifically, 93% of the
failures were in-field, further indicating that there was
likely no recurrence detriment of a reduced PTV margin
[36]. The purpose of the current study is to dosimetrically
evaluate the effect of reduced margin radiotherapy forGBM patients on hippocampal dose compared with
standard margin radiotherapy and determine if there is
likely to be a clinical benefit in terms of improved neuro-
logic function based on previously published hippocampal
radiation/neurocognitive toxicity dose thresholds [31].Methods
Patients
Patients treated for glioblastoma multiforme at our insti-
tution and enrolled on the Radiation Therapy Oncology
Group (RTOG) trial 0825 were identified. RTOG 0825 was
a phase III trial of conventional concurrent chemoradiation
and adjuvant temozolomide plus bevacizumab versus con-
ventional concurrent chemoradiation and adjuvant temozo-
lomide alone in patients with newly diagnosed glioblastoma
[37]. A total of 16 patients, treated post-operatively accord-
ing to RTOG 0825 were included in this analysis.Simulation and planning
CT simulation scans were acquired with patients in the
supine position using a thermoplastic head mask for
immobilization and 3 mm CT slice thickness. Additionally,
post-operative magnetic resonance images (MRI) were used
for treatment planning purposes. The CT simulation image
was registered to the MRI with the use of Velocity AI
(Velocity Medical Solutions, Atlanta, GA) or Brainlab
(Brainlab Inc., Westchester, IL) software. RTOG 0825
required both an initial planning target volume (PTV1)
treated to 46 Gy in 23 fractions and a boost planning
target volume (PTV2) treated to an additional 14 Gy in
7 fractions. In accordance with RTOG 0825 specifications,
the T2 or FLAIR abnormality was expanded by a 2 cm
margin to create the CTV1 and the T1 contrast-enhanced
volume was expanded by 2 cm to create CTV2. Both
CTV’s were expanded by an additional 5 mm to create the
standard margin PTV1 and PTV2. Normal structures
(and dose constraints) required by RTOG 0825 were the
lenses (Dmax = 7 Gy), retinae (Dmax = 50 Gy), optic nerves
(Dmax = 55 Gy), optic chiasm (Dmax = 56 Gy) and brainstem
(Dmax = 60 Gy). The left, right, and bilateral hippocampus
were retrospectively contoured on the T1 post-contrast
MRI and imported into the treatment planning software,
Eclipse (Varian, Palo Alto, CA). Additionally, reduced
margin CTV1 and CTV2 structures were created by
expanding the FLAIR and T1 contrast-enhanced volume
by 8 mm, respectively. The reduced margin PTV1 and
PTV2 were created by expanding the CTV’s by an add-
itional 3 mm. Both the standard margin and reduced
margin PTV’s were planned using a sliding window
IMRT technique with the RTOG normal tissue and target
constraints of less than 10% inhomogeneity within the
target volume and at least 95% of the PTV receiving 100%
of the prescribed dose.
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The primary means of comparing plans were dose-volume
histograms (DVH). The appropriate dose and volume pa-
rameters for OAR were defined and used for comparison.
Additionally, the V95% and V98% for PTV2 was used to
assess target coverage. These parameters were statistically
compared with a paired, two-tailed Student’s t-test with a
significance level of p < 0.05.
Results
Table 1 contains various PTV dosimetric parameters for
both the standard margin and reduced margin plans. It
is seen that volume receiving 95% of the prescribed dose
(V95%) is above 99% of the PTV for both the standard
and reduced margin plans. It would be expected that
there should be equal coverage of the PTV between the
standard margin and reduced margin plans as target
coverage is the effect of the equal PTV constraints imposed
by the operator.
Though the standard margin and reduced margin PTV’s
received similar dose, it is seen from Table 2 that the re-
duced margin volumes translated to statistically significant
reductions in all bilateral hippocampal dosimetric parame-
ters. The reduction in dose varied from 5.3 Gy (8.7%) for
the maximum dose to 12.0 Gy (44.0%) for the D80% with a
17.2 Gy (38.2%) reduction in the median dose. Additionally,
as seen in Figure 1, there are similar reductions in dose
with the reduced margin PTV’s when the bilateral hippo-
campal structure is divided into individual left and right
hippocampal structures.
Discussion
The current study confirms a statistically significant
dosimetric reduction in hippocampal dose with the use
of reduced margin radiotherapy. Specifically, it has been
determined that the hippocampal dose reduction varies
between 8.7% to 44.0% depending on the dosimetric
parameter considered. Though a dose reduction of up to
44% to the hippocampus is quite significant in magnitude,
it remains unclear whether there exists any translatable
improvements in clinical memory function or other neu-
rocognitive endpoints. The most recent study to explore
the link between hippocampus dose and neurocognitive
function is that by Gondi et al. [31] This study involved 29Table 1 Planning tumor volume (PTV2) dosimetric parameter
Standard margin Reduce
Parameter Mean St. Dev. Mean
Max dose (Gy) 63.59 0.96 63.60
Mean dose (Gy) 61.92 0.60 61.94
V98% dose (%) 99.47 0.70 99.47
V95% dose (%) 99.81 0.37 99.72patients with benign or low-grade brain tumors treated
with fractionated stereotactic radiotherapy. Gondi et al.
converted all doses to 2 Gy per fraction biologically
equivalent doses and evaluated neurocognitive function
with the Wechsler Memory Scale-III Word List. They
found that a 2 Gy per fraction equivalent dose (EQD2)
to 40% of the bilateral hippocampi greater than 7.3 Gy
was associated with impaired recall function. Additionally,
they found a significant dose–response relationship with
an of 14.9 Gy to the bilateral hippocampi and a slope of
0.540. Though the hippocampal D40% doses reported in
the current study for both the standard margin PTV
(49.9 Gy) and the reduced margin PTV (36.5 Gy) are
above the 7.3 Gy threshold, this represents an approxi-
mately 13.4 Gy (26.9%) reduction in the hippocampal
D40% dose. Assuming that the dose–response relationship
observed by Gondi et al. continued to be linear with a slope
of 0.540, a 26.9% reduction in hippocampal D40% dose
should translate to a 14.5% improvement on the Wechsler
Memory Scale-III Word Lists Delayed Recall at 18 months.
In addition to Gondi et al., another group has reported a
dose–response relationship for the radiation of the hippo-
campus in low grade or anaplastic gliomas [38]. Of course,
with significantly limited cohort sizes and follow-up, the
quantitative relationship between hippocampal dose and
memory function reported by Gondi et al. and Mahajan
et al. should be applied with an excess of caution and
care [31,38]. However, the reduction of hippocampal
dose with the use of reduced margins in GBM patients
in the context of a potential dose–response relationship
is still encouraging.
Factors that could potentially confound the previously
observed relationship between hippocampal dose and
neurocognitive effects would be secondary effects of sys-
temic agents as well as direct neurocognitive effects of dis-
ease progression [39]. Hahn et al. evaluated patients that
had not received any prior radiotherapy and found worse
cognitive function in patients with left sided lesions and
higher grade gliomas (GBM) [40]. This would indicate
that, at baseline, there is some direct cognitive impairment
from the intracranial disease. In fact, mental status on
presentation has been found to be one of the most signifi-
cant predictors of prognosis for malignant gliomas [41].
Additionally, it has been demonstrated that GBM patientss
d margin
St. Dev. Difference (%) p-value
1.13 −0.006 −0.01% 0.982
1.02 −0.018 −0.03% 0.934
1.36 0.006 0.01% 0.982
0.81 0.089 0.09% 0.596
Table 2 Bilateral hippocampal dosimetric parameters
Standard margin Reduced margin
Parameter Mean St. Dev. Mean St. Dev. Difference (Gy) (%) p-value
Max dose (Gy) 61.4 1.4 56.1 8.6 5.3 8.7% 0.014
Mean dose (Gy) 41.9 9.1 29.9 11.6 12.0 28.7% <0.001
Median dose (Gy) 45.2 17.2 27.9 15.6 17.2 38.2% <0.001
D2% (Gy) 59.9 5.1 53.4 12.1 6.4 10.7% 0.008
D20% (Gy) 57.6 8.5 46.1 16.8 11.5 20.0% 0.001
D40% (Gy) 49.9 14.9 36.5 19.6 13.4 26.9% <0.001
D60% (Gy) 32.7 13.5 18.7 10.9 14.0 42.9% <0.001
D80% (Gy) 27.3 12.1 15.3 10.0 12.0 44.0% <0.001
D98% (Gy) 20.7 9.3 11.8 7.7 8.9 42.9% <0.001
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decline than patients with stable disease, though it was
unclear whether this was due to disease progression or
anti-epileptic use [42]. Anti-epileptic drug use has been
previously implicated in the reduction of most cognitive
functions except memory in a recent study on low-grade
glioma patients [43]. Conversely, corticosteroids have been
demonstrated to directly result in a decline in declarative
and working memory [44]. Additionally, corticosteroids
have been found to result in decreased hippocampal
activity and blood flow [44].
While there are not yet enough data to fully dissect
the specific contribution of radiation therapy to cognitive
decline compared to systemic agents and disease progres-
sion, there is sufficient evidence to indicate that it is aFigure 1 Summation dose-volume histogram (DVH) for the left,
right, and bilateral hippocampal structures comparing standard
and reduced margins.significant factor. As mentioned previously, there is cur-
rently significant interest in mitigating radiation-induced
effects upon the hippocampus as a means to improve
memory and other neurocognitive outcomes in long-term
survivors with metastatic brain disease. The primary means
of reducing radiation dose to the hippocampus has been
to selectively avoid that structure with the use of IMRT.
This is a reasonable approach for brain metastases as
there is published evidence indicating that only 8.6% of
patients have perihippocampal brain metastases and only
3.0% of brain metastases are perihippocampal [45]. In the
current RTOG 0933 protocol studying hippocampal avoid-
ance during whole brain radiation, the perihippocampal
region is defined as the hippocampi with a 5 mm margin
[46]. In the current RTOG 0825 protocol studying the use
of bevacizumab in GBM patients, the PTV is defined as
the GTV with a 2.3 cm to 2.5 cm margin. With such a
large margin on the GTV, it would be difficult to selectively
avoid the hippocampus in a majority of GBM lesions [37].
Using only the McDonald et al. reduced GBM margin
of 1.2 cm from the GTV to the PTV (without selective
hippocampal avoidance), this study has demonstrated up
to a 44% reduction in dose to the hippocampus compared
to standard RTOG margins. Additional hippocampal dose
reduction may be expected with selective hippocampal
avoidance in GBM patients. Though there is not yet an
active hippocampal sparing protocol for GBM patients,
the reduced margins from MacDonald et al. should safely
enable hippocampal sparing in a greater proportion of
GBM patients than standard margins [36].
A trial could conceivably be conducted to evaluate and
quantify the neurocognitive benefits of reduced margin
radiation therapy for GBM patients. Such a trial would
likely require patients to be randomized between a stand-
ard margin arm (2.3 cm to 2.5 cm) and a reduced margin
arm. Both arms would then receive identical Temodar
treatment. The primary evaluated outcome would be neu-
rocognitive function and the secondary outcomes would
include radiographic progression, overall survival, and
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contoured as part of the trial and hippocampal dosimetric
data from the treatment plan (Dmax, D40%, etc.) could then
be correlated with late neurocognitive effects to generate
further insight into the dose–response relationship of the
hippocampal organ.
Conclusions
This study builds upon previously published data demon-
strating the safety and efficacy of reduced PTV margins for
GBM patients by dosimetrical evaluating and quantifying
the effect of the reduced margins on hippocampal dose.
It was found that a hippocampal dose reduction of 8.7%
to 44% may be realized with the reduced PTV margins
compared to standard RTOG 0825 margins for GBM
patients. It is anticipated the reduced PTV margins will
also allow selective hippocampal sparing in a greater pro-
portion of GBM patients compared to standard margins.
While the exact clinical benefit of this dose reduction is
currently unclear, this study does provide support for a
prospective clinical trial investigating the neurocognitive
benefits of reduced margin radiotherapy and hippocampal
sparing for GBM patients.
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